Krystal Biotech Inc
NASDAQ:KRYS

Watchlist Manager
Krystal Biotech Inc Logo
Krystal Biotech Inc
NASDAQ:KRYS
Watchlist
Price: 144.36 USD 5.02% Market Closed
Market Cap: 4.2B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+10%
Revenue
Forecast
+9%
Net Income
Forecast
+19%

Wall Street
Price Targets

KRYS Price Targets Summary
Krystal Biotech Inc

Wall Street analysts forecast KRYS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KRYS is 209.93 USD with a low forecast of 167.66 USD and a high forecast of 264.6 USD.

KRYS Lowest Forecast
Wall Street Target
167.66 USD
16% Upside
KRYS Average Forecast
Wall Street Target
209.93 USD
45% Upside
KRYS Highest Forecast
Wall Street Target
264.6 USD
83% Upside
Lowest
Price Target
167.66 USD
16% Upside
Average
Price Target
209.93 USD
45% Upside
Highest
Price Target
264.6 USD
83% Upside
Krystal Biotech Inc Competitors:
Price Targets
4
4BB
4Basebio PLC
106% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
25% Upside
HPHA
Heidelberg Pharma AG
292% Upside
F
FENC
Fennec Pharmaceuticals Inc
56% Upside
4
4BB
4Basebio PLC
106% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
25% Upside
HPHA
Heidelberg Pharma AG
292% Upside
F
FENC
Fennec Pharmaceuticals Inc
56% Upside
BEAM
Beam Therapeutics Inc
112% Upside
AUPH
Aurinia Pharmaceuticals Inc
7% Downside
688687
Beijing Kawin Technology Share-holding Co Ltd
60% Upside
LENZ
Graphite Bio Inc
24% Upside

Revenue
Forecast

Revenue Estimate
Krystal Biotech Inc

The compound annual growth rate of Krystal Biotech Inc's revenue for the next 3 years is 45%.

N/A
Past Growth
45%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Krystal Biotech Inc

The compound annual growth rate of Krystal Biotech Inc's operating income for the next 3 years is 56%.

N/A
Past Growth
56%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Krystal Biotech Inc

The compound annual growth rate of Krystal Biotech Inc's net income for the next 3 years is 53%.

N/A
Past Growth
53%
Estimated Growth
Estimates Accuracy
-39%
Average Miss
What are analyst estimates?

See Also

Summary
KRYS intrinsic value, competitors valuation, and company profile.
DCF Valuation
KRYS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KRYS stock valuation using valuation multiples.
Wall Street Estimates
KRYS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KRYS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KRYS's stock price target?
Price Target
209.93 USD

According to Wall Street analysts, the average 1-year price target for KRYS is 209.93 USD with a low forecast of 167.66 USD and a high forecast of 264.6 USD.

What is Krystal Biotech Inc's Revenue forecast?
Projected CAGR
45%

The compound annual growth rate of Krystal Biotech Inc's revenue for the next 3 years is 45%.

What is Krystal Biotech Inc's Operating Income forecast?
Projected CAGR
56%

The compound annual growth rate of Krystal Biotech Inc's operating income for the next 3 years is 56%.

What is Krystal Biotech Inc's Net Income forecast?
Projected CAGR
53%

The compound annual growth rate of Krystal Biotech Inc's net income for the next 3 years is 53%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 281,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.